Category Archives: Top News

Agios Pharma Receives a Hold from Oppenheimer

In a report released today, Leah R. Cann from Oppenheimer assigned a Hold rating to Agios Pharma (NASDAQ: AGIO). The company’s shares opened today at $91.41. Cann commented: “We had anticipated FDA approval of Tibsovo (ivosidenib/AG-120) in late-August 2018. With

General Motors Receives a Buy from Guggenheim

Guggenheim analyst Emmanuel Rosner reiterated a Buy rating on General Motors (NYSE: GM) yesterday and set a price target of $52. The company’s shares opened today at $39.07. According to TipRanks.com, Rosner is a 1-star analyst with an average return

Stifel Nicolaus Believes Facebook (NASDAQ: FB) Won’t Stop Here

In a report released yesterday, Scott Devitt from Stifel Nicolaus reiterated a Buy rating on Facebook (NASDAQ: FB), with a price target of $242. The company’s shares closed yesterday at $208.09, close to its 52-week high of $210.99. According to

RBC Capital Believes Bank of Montreal (TSX: BMO) Won’t Stop Here

On July 18, an analyst has provided a rating update for the Financial sector company, Bank of Montreal (TSX: BMO). Darko Mihelic, an analyst with RBC Capital, has upgraded their rating on BMO to Buy on July 18 , with

Oppenheimer Sticks to Its Hold Rating for Intercept Pharma

In a report released yesterday, Jay Olson from Oppenheimer maintained a Hold rating on Intercept Pharma (NASDAQ: ICPT), with a price target of $100. The company’s shares closed yesterday at $96. Olson observed: “We update our ICPT model to reflect

KeyBanc Assigns a Buy Rating on Microsoft

In a report released today, Brent Bracelin from KeyBanc assigned a Buy rating to Microsoft (NASDAQ: MSFT), with a price target of $110. The company’s shares opened today at $105.95, close to its 52-week high of $106.50. Bracelin commented: “We